User contributions for Omid Afkhami-Ardakani
A user with 10 edits. Account created on 18 July 2024.
21 December 2024
- 13:1413:14, 21 December 2024 diff hist +5,804 N Pitolisant Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pitolisant |aOrAn=a |drugClass=Histamine-3 (H3) Receptor Antagonist/Inverse Agonist |indicationType=treatment |indication=Excessive daytime sleepiness (EDS) or cataplexy in adult patients and in pediatric patients aged 6 years and older with narcolepsy. |adverseReactions=Insomnia, Nausea, Anxiety, Headache, Irritability, Dizziness, Depression, Tremor, Sleep disorders, Fatigue, Vomiting, Vertigo, Dy..." current
8 December 2024
- 18:3318:33, 8 December 2024 diff hist +5,733 N Pretomanid Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pretomanid |aOrAn=a |drugClass=Nitroimidazooxazine Antimycobacterial |indicationType=treatment |indication=Pulmonary extensively drug-resistant (XDR) tuberculosis (TB), Treatment-intolerant or nonresponsive multidrug-resistant (MDR) pulmonary TB |adverseReactions=Peripheral neuropathy, Acne, Anemia, Nausea, Vomiting, Headache, Increased transaminases, Dyspepsia, Rash, and Decreased appetite. |fdaLI..." current
- 17:5517:55, 8 December 2024 diff hist +5,904 N Pexidartinib Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Pexidartinib |aOrAn=a |drugClass=Tyrosine Kinase Inhibitor |indicationType=treatment |indication=Tenosynovial Giant Cell Tumor (TGCT). |hasBlackBoxWarning=Yes |adverseReactions=Increased liver enzymes (e.g., AST, ALT), Hair color changes, Increased cholesterol levels, Decreased white blood cell counts, Fatigue, Edema, Rash, and Dysgeusia (altered taste). Decreased phosphate levels |blackBoxWarning..." current
24 November 2024
- 17:0317:03, 24 November 2024 diff hist +4,366 N Nubeqa Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Darolutamide |aOrAn=a |drugClass=Nonsteroidal Antiandrogen (NSAA) |indicationType=treatment |indication=Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) in adult men. It can also be used for treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in combination with docetaxel in adult men. |adverseReactions=Fatigue, Pain in extremities, Rash, Decreased neutrophil count, and I..." current
17 November 2024
- 17:2717:27, 17 November 2024 diff hist +3,269 N Accrufer Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Ferric Maltol |aOrAn=an |drugClass=Oral Iron Replacement Therapy |indicationType=treatment |indication=iron deficiency in adults. |adverseReactions=Flatulence, diarrhea, constipation, discolored stools, abdominal pain, nausea, vomiting, and abdominal discomfort or bloating. |fdaLIADAdult=The recommended dosage is 30 mg orally twice daily, taken 1 hour before or 2 hours after a meal. |contraindicati..." current
2 November 2024
- 20:1220:12, 2 November 2024 diff hist +4,265 N Recarbrio Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Imipenem, Cilastatin, and Relebactam |aOrAn=an |drugClass=Antibacterial Combination |indicationType=treatment |indication=Complicated Urinary Tract Infections (cUTI), Complicated Intra-Abdominal Infections (cIAI), and Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) in patients 18 years and older. |adverseReactions=Nausea, Diarrhea, Headache, Fever, an..." current
25 October 2024
- 21:3921:39, 25 October 2024 diff hist +21 m Selinexor No edit summary current Tag: Visual edit
- 21:3221:32, 25 October 2024 diff hist +3,815 N Selinexor Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Selinexor |aOrAn=a |drugClass=Selective Inhibitor of Nuclear Export (SINE) |indicationType=treatment |indication=Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B-Cell Lymphoma (DLBCL) |hasBlackBoxWarning=Yes |adverseReactions=Nausea, fatigue, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, weight loss |blackBoxWarningTitle=Serious Hematologic a..."
16 October 2024
- 16:4116:41, 16 October 2024 diff hist +6,144 N Vyleesi Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Vyleesi |aOrAn=a |drugClass=Melanocortin receptor agonist |indicationType=treatment |indication=hypoactive sexual desire disorder (HSDD) in premenopausal women |adverseReactions=nausea (40%), flushing (20%), injection site reactions (13%), headache (11%), and vomiting (4.8%) |fdaLIADAdult=Vyleesi is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in pre..." current
19 September 2024
- 15:0215:02, 19 September 2024 diff hist +12,965 N Polivy Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami Ardakani |genericName=Polivy |aOrAn=a |drugClass=HUMAN PRESCRIPTION DRUG LABEL |indicationType=treatment |indication=POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: 1. in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise speci..." current